The impact of neoadjuvant and adjuvant immunotherapy on the survival of pancreatic cancer patients: a retrospective analysis

Table 3 Cox regression analysis of only neoadjuvant immunotherapy combinations

Variable		N (%)	Univariable analysis		Multivariable analysis
Variable		N (%)	Hazard Ratio (95% CI)	P	Hazard Ratio (95% CI)	P
Immunotherapy	Neoadjuvant immunotherapy	373 (1.09)	0.88 (0.78–0.98)	0.026	0.93 (0.82–1.05)	0.220
Immunotherapy	No immunotherapy	33,921 (98.91)	Ref		Ref
CTx plus immunotherapy	Neoadjuvant CTx plus imm	95 (0.53)	0.835 (0.653–1.067)	0.150	0.930 (0.725–1.195)	0.572
CTx plus immunotherapy	Adjuvant CTx only	17,868 (99.47)	Ref
CTxRT plus immunotherapy	Neoadjuvant CTxRTx plus imm	258 (1.64)	0.897 (0.781–1.030)	0.122	0.942 (0.814–1.091)	0.425
CTxRT plus immunotherapy	Adjuvant CTxRTx only	15,466 (98.36)	Ref

ISSN: 1471-2407